These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 9703473

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
    Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, Lapointe GR, Feucht PH, Warne RL, Heise CC, Menezes D, Aardalen K, Ye H, He M, Le V, Vora J, Jansen JM, Wernette-Hammond ME, Harris AL.
    J Med Chem; 2009 Jan 22; 52(2):278-92. PubMed ID: 19113866
    [Abstract] [Full Text] [Related]

  • 25. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
    Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK, Gruber BC, Ye F, Hallett WA, Nilakantan R, Shen R, Wang YF, Greenberger LM, Tsou HR.
    J Med Chem; 2003 Jan 02; 46(1):49-63. PubMed ID: 12502359
    [Abstract] [Full Text] [Related]

  • 26. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S, Zheng Y, Jun X, Mahajan S, Mao C, Sudbeck EA, Uckun FM.
    Clin Cancer Res; 1999 Dec 02; 5(12):4264-72. PubMed ID: 10632369
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 02; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 29. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.
    J Med Chem; 1999 May 20; 42(10):1803-15. PubMed ID: 10346932
    [Abstract] [Full Text] [Related]

  • 30. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.
    Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, Leopold WR.
    Anticancer Drug Des; 1994 Aug 20; 9(4):331-51. PubMed ID: 7916900
    [Abstract] [Full Text] [Related]

  • 31. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA, Spicer JA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA.
    J Med Chem; 1999 Jul 01; 42(13):2383-93. PubMed ID: 10395479
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB.
    Cancer Res; 1996 Jan 01; 56(1):100-4. PubMed ID: 8548747
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 01; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 35. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S, Narla RK, Zheng Y, Liu XP, Jun X, Mao C, Sudbeck EA, Uckun FM.
    Anticancer Drug Des; 1999 Oct 01; 14(5):403-10. PubMed ID: 10766295
    [Abstract] [Full Text] [Related]

  • 36. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE, Reddy DR, Iqbal MA, Singh J, Aimone LD, Angeles TS, Albom M, Yang S, Ator MA, Meyer SL, Robinson C, Ruggeri BA, Dionne CA, Vaught JL, Mallamo JP, Hudkins RL.
    J Med Chem; 2003 Dec 04; 46(25):5375-88. PubMed ID: 14640546
    [Abstract] [Full Text] [Related]

  • 37. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
    McDermott LA, Simcox M, Higgins B, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Luk KC.
    Bioorg Med Chem; 2005 Aug 15; 13(16):4835-41. PubMed ID: 15953730
    [Abstract] [Full Text] [Related]

  • 38. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.
    Cancer Res; 2001 Oct 01; 61(19):7196-203. PubMed ID: 11585755
    [Abstract] [Full Text] [Related]

  • 39. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
    J Pharmacol Exp Ther; 2012 Dec 01; 343(3):617-27. PubMed ID: 22935731
    [Abstract] [Full Text] [Related]

  • 40. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4848-58. PubMed ID: 11156244
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.